Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Alliance for Clinical Trials in Oncology
Status
Active, not recruiting
NCT ID
NCT03087708
This randomized pilot clinical trial studies the side effects and best dose of naloxegol and
to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.
Naloxegol may relieve some of the side effects of opioid pain medication and fight off future
growth in the cancer.
Intervention
Naloxegol, Placebo, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Condition
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Investigators
Pankaj Gupta, MD

See list of participating sites